Business Description
Corcept Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US2183521028
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2438.55 | |||||
Equity-to-Asset | 0.82 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 15.51 | |||||
Beneish M-Score | -2.24 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.9 | |||||
3-Year EBITDA Growth Rate | -2.2 | |||||
3-Year EPS without NRI Growth Rate | 3.4 | |||||
3-Year FCF Growth Rate | -2.2 | |||||
3-Year Book Growth Rate | 3 | |||||
Future 3-5Y Total Revenue Growth Rate | 17.22 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 25.78 | |||||
9-Day RSI | 35.04 | |||||
14-Day RSI | 41.52 | |||||
6-1 Month Momentum % | -18.94 | |||||
12-1 Month Momentum % | 5.94 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.39 | |||||
Quick Ratio | 4.31 | |||||
Cash Ratio | 3.52 | |||||
Days Inventory | 390.42 | |||||
Days Sales Outstanding | 26.02 | |||||
Days Payable | 735.11 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 4 | |||||
Shareholder Yield % | 0.08 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 98.66 | |||||
Operating Margin % | 22.24 | |||||
Net Margin % | 22 | |||||
FCF Margin % | 26.44 | |||||
ROE % | 21.92 | |||||
ROA % | 18.04 | |||||
ROIC % | 68.03 | |||||
ROC (Joel Greenblatt) % | 12606.58 | |||||
ROCE % | 21.71 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 24.21 | |||||
Forward PE Ratio | 147.06 | |||||
PE Ratio without NRI | 24.21 | |||||
Shiller PE Ratio | 34.99 | |||||
Price-to-Owner-Earnings | 29.45 | |||||
PEG Ratio | 4.48 | |||||
PS Ratio | 5.32 | |||||
PB Ratio | 4.69 | |||||
Price-to-Tangible-Book | 4.69 | |||||
Price-to-Free-Cash-Flow | 20.18 | |||||
Price-to-Operating-Cash-Flow | 20.18 | |||||
EV-to-EBIT | 18.83 | |||||
EV-to-EBITDA | 18.42 | |||||
EV-to-Revenue | 4.19 | |||||
EV-to-Forward-Revenue | 3.29 | |||||
EV-to-FCF | 15.9 | |||||
Price-to-Projected-FCF | 1.06 | |||||
Price-to-Median-PS-Value | 0.62 | |||||
Price-to-Graham-Number | 2.25 | |||||
Price-to-Net-Current-Asset-Value | 6.91 | |||||
Price-to-Net-Cash | 9.37 | |||||
Earnings Yield (Greenblatt) % | 5.31 | |||||
FCF Yield % | 5.32 | |||||
Forward Rate of Return (Yacktman) % | 9.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Corcept Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 447.312 | ||
EPS (TTM) (€) | 0.881 | ||
Beta | 0.24 | ||
Volatility % | 62.23 | ||
14-Day RSI | 41.52 | ||
14-Day ATR (€) | 0.529017 | ||
20-Day SMA (€) | 22.556 | ||
12-1 Month Momentum % | 5.94 | ||
52-Week Range (€) | 17.9 - 31.6 | ||
Shares Outstanding (Mil) | 103.84 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Corcept Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Corcept Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Corcept Therapeutics Inc Frequently Asked Questions
What is Corcept Therapeutics Inc(STU:HTD)'s stock price today?
When is next earnings date of Corcept Therapeutics Inc(STU:HTD)?
Does Corcept Therapeutics Inc(STU:HTD) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |